Tobacco.org

NRT Smoking Cessation Aids in the US - Chantix Sales Declined by 30% in the US in 2008  

Research and Markets (http://www.researchandmarkets.com/research/dbf721/nrt_smoking_cessat) has announced the addition of the "NRT Smoking Cessation Aids in the US" report to their offering.

NRT smoking cessation value declined for the second year in a row in 2008, although the drop was less dramatic than that of 2007. Declines in 2007 were driven by the huge popularity of Chantix, an Rx remedy launched by Pfizer in 2006, and the growing strength of private label smoking cessation products, most notably private label NRT lozenges, which were approved in 2006. Private label products continued to hamper value growth in 2008, as consumers looking to quit smoking opted for cheaper alternatives. However, the impact of Chantix on the OTC NRT sector was negligible, as Chantix sales actually declined by 30% in the US in 2008.

Jump to full article »